Corporate Marks means the registered or unregistered trade marks and service marks, house marks and marks of ownership, trading names, brand names, distinctive colour schemes, devices, styles, emblems and other manifestations associated with BT and/or the Communications Provider and in the case of BT including logotype comprising the letters BT and the piper device and/or letters BT and the connected world device and/or any elements of these marks;”
Corporate Marks means the registered or unregistered trademarks and Infrastructure Service marks, house marks and marks of ownership, trading names, brand names, domain names, distinctive colour schemes, devices, styles, emblems and other manifestations associated with BT and/or the Developer and in the case of BT including the logotype comprising the letters BT and the piper device and/or the letters BT and the connected world device and/or any elements of these marks;
Corporate Marks means the trademarks, service marks, trade names and related logos and designs owned by General Motors as of the date hereof, a listing of which General Motors will provide at least 30 days prior to the Closing Date.
Examples of Corporate Marks in a sentence
The Customer shall not make use of or permit anyone else to make use of the BT Corporate Marks or the BT name or any element thereof either alone or in combination with another word or device mark, nor any other brand, get-up or trade mark of BT or its affiliated companies, where such use constitutes or would constitute an infringement of BT’s registered trade mark or common law rights.
Except as provided in this Clause 9 the Communications Provider shall not make use of or permit anyone else to make use of the BT Corporate Marks or the BT name or any element thereof either alone or in combination with another word or device mark, nor any other brand, get-up or trade mark of BT or its affiliated companies, where such use constitutes or would constitute an infringement of BT’s registered trade mark or common law rights.
Permission to use the AMCB Certification Marks, identified below, does not constitute permission to use the AMCB Corporate Marks.
All goodwill associated with or attached to the Tocagen Corporate Marks arising out of the use thereof by Apollo, its Affiliates and Sublicensees shall inure to the benefit of Tocagen.
The Customer agrees not to: (b) use any Immervox Intellectual Property Rights or Immervox Corporate Marks; (c) authorise any third party to use any of Immervox’s or its partner’s Intellectual Property Rights or Corporate Marks; or (d) use any photographs or representations of any Immervox or its partner’s buildings including in any promotional literature, without the prior written consent of Immervox.
More Definitions of Corporate Marks
Corporate Marks means, with respect to each of the Parties, the corporate name of such Party or those of Affiliates of such Party, and its and their trade names, trademarks, service marks, domain names, and associated logos and designs; provided that Corporate Marks shall not include the Product Trademarks or the Licensed LCP Xxxx.
Corporate Marks means the registered or unregistered trademarks and service marks, house marks and marks of ownership, trading names, brand names, distinctive colour schemes, devices, styles, emblems and other manifestations associated with Xoom and/or any of our suppliers;
Corporate Marks means the trademarks, service marks, trade names and related logos and designs owned by General Motors as of the date hereof, a listing of which General Motors will provide at least 30 days prior to the Closing Date. “Cross-License Agreement” has the meaning set forth in Section 6.5(h) “Data Room” means the data room comprising the documents and other information made available by General Motors to the Buyer from January 6, 2017 until February 28, 2017 (midnight ET), a certified copy of which is delivered by General Motors to the Buyer on the date hereof.
Corporate Marks means the registered or unregistered trade marks and service marks, house marks and marks of ownership, trading names, brand names, domain names, distinctive colour schemes, devices, styles, emblems and other manifestations associated with BT and/or the Communications Provider and in the case of BT including the logotype comprising the letters BT and the piper device and/or the letters BT and the connected world device and/or any elements of these marks; “CP Requirement Date” is the date the Communications Provider requests the Service should be installed and commissioned by BT and be available for use by the Communications Provider;
Corporate Marks means, (a) in the case of Merck, the corporate Trademarks owned by Merck or its Affiliates as Merck may designate in writing to SeaGen from time to time (each, a “Merck Corporate Xxxx”) and (b) in the case of SeaGen, the corporate Trademarks owned by SeaGen or its Affiliates as SeaGen may designate in writing to Merck from time to time (each, an “SeaGen Corporate Xxxx”), including for the purposes of both clause (a) and (b), any translation or derivation of any of the foregoing, either alone or in combination with other words and all marks, trade dress, logos, monograms, domain name registrations and other source identifiers confusingly similar to or embodying any of the foregoing either alone or in combination with other words. 1.39 “Cost of Goods Manufactured” means the cost to produce a given quantity of Licensed Product by a Party or its Affiliate, as calculated in accordance with Schedule 1.39, including taking into account in such calculation any other capital expenditure, costs and expenses approved as Cost of Goods Manufactured under Section 3.4.2(o). 1.40 “Develop” means (a) to research, develop, analyze, test and conduct non-clinical, preclinical (including GLP Tox Studies), clinical and all other regulatory studies and trials for a Licensed Compound or the Licensed Product, as applicable, including new indications and new combinations, (b) all activities pertaining to CMC Development and formulation development (including new formulations), (c) all other activities related to securing and maintaining Marketing Authorization for a Licensed Compound or the Licensed Product, as applicable, and regulatory activities in connection therewith and (d) medical affairs activities for the Licensed Product. Development may also include the foregoing activities, if any, with respect to any Companion Diagnostic, which activities, if any, shall be set forth in the relevant Development Plan with respect to a Companion Diagnostic for a Licensed Compound or the Licensed Product, as applicable. “Developing” and “Development” shall have correlative meanings. 1.41 “Development Budget” means the budget for the Development of the Licensed Product for the Territory, as set forth in the applicable Development Plan, as the same may be amended from time to time in accordance with this Agreement. 1.42 “Development Costs” means the sum of (a) Development FTE Costs and Medical Affairs FTE Costs and (b) out-of-pocket costs and expenses, incurred by a Party or any of its Affil...
Corporate Marks means the registered or unregistered trademarks and service marks, house marks and marks of ownership, trading names, brand names, domain names, distinctive colour
Corporate Marks means the ImClone Company Marks and UCB Company Marks. Data Package means, with respect to an Antibody Product for an Independent Indication or a Competing Product (a) for which a Drug Approval Application has not been approved by the Regulatory Authorities in the United States, including the FDA, or Europe, including the EMEA, (i) a summary of all the relevant clinical data with respect to the Independent Indication for the Antibody Product or to the Competing Product, as applicable, including any Clinical Study results and resultant data analyses, (ii) any regulatory submissions made to the FDA or any other Regulatory Authority by or on behalf of the Continuing Party with respect to such Independent Indication for such Antibody Product or to such Competing Product, (iii) protocols for any ongoing Clinical Studies and proposed designs for any anticipated Clinical Studies with respect to such Independent Indication for such Antibody Product or to such Competing Product, (iv) a budget for the costs and expenses expected to be incurred in connection with any ongoing Development of such Independent Indication for such Antibody Product or Competing Product and, (v) such other material Information and Materials relating to such Independent Indication for such Antibody Product or to such Competing Product in the control of the Continuing Party that were not previously disclosed to the Non-Continuing Party and that were relied on by the Continuing Party’s senior management in determining to proceed with the current phase of Development of such Independent Indication for such Antibody Product or of such Competing Product, and (b) for which a Drug Approval Application has been approved by the Regulatory Authorities in the United States, including the FDA, or Europe, including the EMEA, a copy of such Drug Approval Application and any other filings made with the Regulatory Authorities with respect to the Antibody Product for such Independent Indication or the Competing Product.